Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Merck & Company (MRK) NYSE

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]] [[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]] [[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
3-Month Performance
View Chart

Fundamentals

See More
  • Market Capitalization, $K 168,654,144
  • Shares Outstanding, K 2,765,210
  • Annual Sales, $ 39,498 M
  • Annual Income, $ 4,442 M
  • 36-Month Beta 0.77
  • Price/Sales 4.17
  • Price/Book 3.80

Price Performance

See More
Period Period Low Period High Performance
1-Month
58.56 +6.78%
on 12/30/16
63.24 -1.12%
on 01/12/17
+2.03 (+3.36%)
since 12/20/16
3-Month
58.29 +7.27%
on 11/03/16
65.46 -4.48%
on 11/10/16
+0.61 (+0.99%)
since 10/20/16
52-Week
47.97 +30.35%
on 02/08/16
65.46 -4.48%
on 11/10/16
+11.98 (+23.70%)
since 01/20/16

Most Recent Stories

More News
Bristol-Myers Squibb and Ono Pharmaceutical Company Enter Settlement and License Agreement with Merck to Resolve PD-1 Antibody Patent Litigation

--Ends all global patent-infringement litigation against Merck's sale of Keytruda

Merck Announces Settlement and License Agreement Resolving KEYTRUDA(R) (pembrolizumab) Patent Litigation

Merck (NYSE:MRK), known as MSD outside the United States and Canada), and certain of its affiliates, today announced it agreed to enter into a settlement and license agreement with Bristol-Myers...

Bristol-Myers to Not Seek Accelerated Approval for Opdivo+Yervoy

Bristol-Myers (BMY) won't seek an accelerated approval in the U.S. for the combination of its two immuno-oncology treatments Opdivo plus Yervoy for the first-line lung cancer.

Celgene (CELG) Q4 Earnings: Will the Stock Pull a Surprise?

Celgene Corporation (CELG), which is set to report fourth-quarter 2016 results on Jan 26, reported a positive earnings surprise of 6.11% last quarter.

BioLineRx (BLRX) Starts Cancer Study on BL-8040+Keytruda

BioLineRx (BLRX) announced the initiation of a second phase IIa study on BL-8040 in combination with Keytruda for the treatment of pancreatic cancer.

Bristol-Myers (BMY) Q4 Earnings: Will the Stock Disappoint?

Bristol-Myers (BMY) is set to report fourth-quarter 2016 results on Jan 26. It reported a positive earnings surprise of 18.46% in the last quarter.

MSD for Mothers Commits $10 Million and Business Expertise to the Global Financing Facility to Help End Preventable Deaths of Mothers

MSD, known as Merck & Co., Inc., Kenilworth, N.J., U.S.A., inside the United States and Canada, announced today its $10 million commitment to the Global Financing Facility (GFF) in support...

AstraZeneca Offers Update on Immuno-Oncology Program

AstraZeneca (AZN) provided an update on its late-stage immuno-oncology program for first-line NSCLC.

Agenus, NCI Ink Deal to Evaluate Prophage-Keytruda Combo

Agenus (AGEN) entered into a clinical trial collaboration with the National Cancer Institute to evaluate Prophage, in conjunction with Merck's (MRK) Keytruda.

Research and Markets - Immuno-Oncology Market, 2022: Key Players are Amgen, Bristol-Myers Squibb, F. Hoffmann-La Roche, and Merck

DUBLIN, Jan 18, 2017 /PRNewswire/ --

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Buy with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak.

See More

Business Summary

Merck & Co., Inc. is a global research-driven pharmaceutical company dedicated to putting patients first. Established in 1891, Merck discovers, develops, manufactures and markets vaccines and medicines to address unmet medical needs. The company devotes extensive efforts to increase access to medicines...

See More

Support & Resistance

2nd Resistance Point 63.30
1st Resistance Point 62.92
Last Price 62.53
1st Support Level 62.15
2nd Support Level 61.76

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.